Report Detail

Request for Sample of this report

Pharma & Healthcare Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

  • RnM4627698
    • |
  • 26 September, 2025
    • |
  • Global
    • |
  • 103 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size was valued at US$ 5711 million in 2024 and is forecast to a readjusted size of USD 10170 million by 2031 with a CAGR of 8.7% during review period.
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment. In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
Market Driver: The increasing prevalence of cancer, particularly ovarian, breast, and prostate cancers, is a major driver of the PARP inhibitors market. As targeted therapies become more popular for cancer treatment, PARP inhibitors, which work by blocking the repair of DNA damage in cancer cells, have shown promising results in clinical trials, especially for patients with specific genetic mutations such as BRCA1 and BRCA2. The growing recognition of the effectiveness of PARP inhibitors in both monotherapy and combination treatments is driving demand, as these therapies offer personalized treatment options with fewer side effects compared to traditional chemotherapy. Ongoing research and the expansion of indications for PARP inhibitors in other cancers also contribute to market growth.
Market Challenge: One of the key challenges for the PARP inhibitors market is the high cost of these therapies, which limits patient access and increases the financial burden on healthcare systems. Despite their effectiveness, the prices of PARP inhibitors are often prohibitively expensive, particularly for long-term use. Additionally, not all cancer patients benefit from PARP inhibition, and there is a risk of resistance developing over time, which can reduce the long-term efficacy of the drugs. Regulatory hurdles and the need for further clinical evidence to support broader indications also pose challenges to market expansion. As the market evolves, ensuring access and affordability while continuing to innovate will be critical to overcoming these barriers.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%. North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent. In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
This report is a detailed and comprehensive analysis for global PARP (Poly ADP-Ribose Polymerase) Inhibitor market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PARP (Poly ADP-Ribose Polymerase) Inhibitor
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK, Zai Lab, Hengrui Medical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
PARP (Poly ADP-Ribose Polymerase) Inhibitor market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
Market segment by Application
Ovarian Cancer
Breast Cancer
Other
Major players covered
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Hengrui Medical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, with price, sales quantity, revenue, and global market share of PARP (Poly ADP-Ribose Polymerase) Inhibitor from 2020 to 2025.
Chapter 3, the PARP (Poly ADP-Ribose Polymerase) Inhibitor competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PARP (Poly ADP-Ribose Polymerase) Inhibitor breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and PARP (Poly ADP-Ribose Polymerase) Inhibitor market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of PARP (Poly ADP-Ribose Polymerase) Inhibitor.
Chapter 14 and 15, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Lynparza
    • 1.3.3 Zejula
    • 1.3.4 Rubraca
    • 1.3.5 Talzenna
    • 1.3.6 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Ovarian Cancer
    • 1.4.3 Breast Cancer
    • 1.4.4 Other
  • 1.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size & Forecast
    • 1.5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity (2020-2031)
    • 1.5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 AstraZeneca
    • 2.1.1 AstraZeneca Details
    • 2.1.2 AstraZeneca Major Business
    • 2.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
    • 2.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 AstraZeneca Recent Developments/Updates
  • 2.2 Tesaro
    • 2.2.1 Tesaro Details
    • 2.2.2 Tesaro Major Business
    • 2.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
    • 2.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Tesaro Recent Developments/Updates
  • 2.3 Merck & Co
    • 2.3.1 Merck & Co Details
    • 2.3.2 Merck & Co Major Business
    • 2.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
    • 2.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Merck & Co Recent Developments/Updates
  • 2.4 Clovis Oncology
    • 2.4.1 Clovis Oncology Details
    • 2.4.2 Clovis Oncology Major Business
    • 2.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
    • 2.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Clovis Oncology Recent Developments/Updates
  • 2.5 Pfizer
    • 2.5.1 Pfizer Details
    • 2.5.2 Pfizer Major Business
    • 2.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
    • 2.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Pfizer Recent Developments/Updates
  • 2.6 GSK
    • 2.6.1 GSK Details
    • 2.6.2 GSK Major Business
    • 2.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
    • 2.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 GSK Recent Developments/Updates
  • 2.7 Zai Lab
    • 2.7.1 Zai Lab Details
    • 2.7.2 Zai Lab Major Business
    • 2.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
    • 2.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Zai Lab Recent Developments/Updates
  • 2.8 Hengrui Medical
    • 2.8.1 Hengrui Medical Details
    • 2.8.2 Hengrui Medical Major Business
    • 2.8.3 Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Product and Services
    • 2.8.4 Hengrui Medical PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Hengrui Medical Recent Developments/Updates

3 Competitive Environment: PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturer

  • 3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturer (2020-2025)
  • 3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2024
    • 3.4.3 Top 6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2024
  • 3.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Overall Company Footprint Analysis
    • 3.5.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Region Footprint
    • 3.5.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Company Product Type Footprint
    • 3.5.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region
    • 4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2020-2031)
    • 4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2020-2031)
    • 4.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Region (2020-2031)
  • 4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2020-2031)
  • 4.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2020-2031)
  • 4.4 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2020-2031)
  • 4.5 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2020-2031)
  • 4.6 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2020-2031)
  • 5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Type (2020-2031)
  • 5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2020-2031)
  • 6.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Application (2020-2031)
  • 6.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Application (2020-2031)

7 North America

  • 7.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2020-2031)
  • 7.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2020-2031)
  • 7.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
    • 7.3.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2020-2031)
    • 7.3.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2020-2031)
  • 8.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2020-2031)
  • 8.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
    • 8.3.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Region
    • 9.3.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2020-2031)
  • 10.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2020-2031)
  • 10.3 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
    • 10.3.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2020-2031)
    • 10.3.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
    • 11.3.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Drivers
  • 12.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Restraints
  • 12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of PARP (Poly ADP-Ribose Polymerase) Inhibitor and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of PARP (Poly ADP-Ribose Polymerase) Inhibitor
  • 13.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Distributors
  • 14.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on PARP (Poly ADP-Ribose Polymerase) Inhibitor. Industry analysis & Market Report on PARP (Poly ADP-Ribose Polymerase) Inhibitor is a syndicated market report, published as Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031. It is complete Research Study and Industry Analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo